4.6 Article

A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein

期刊

MOLECULAR CANCER THERAPEUTICS
卷 13, 期 6, 页码 1492-1502

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-13-0689

关键词

-

类别

资金

  1. National Cancer Institute's Initiative for Chemical Genetics (ICG) [N01-CO-12400]
  2. Cancer Target Discovery and Development (CTD2) Network [RC2 CA148399]
  3. New Innovator Award from the National Institutes of Health
  4. Challenge Award from the Prostate Cancer Foundation

向作者/读者索取更多资源

Members of the ETS transcription factor family have been implicated in several cancers, where they are often dysregulated by genomic derangement. ETS variant 1 (ETV1) is an ETS factor gene that undergoes chromosomal translocation in prostate cancers and Ewing sarcomas, amplification in melanomas, and lineage dysregulation in gastrointestinal stromal tumors. Pharmacologic perturbation of ETV1 would be appealing in these cancers; however, oncogenic transcription factors are often deemed undruggable by conventional methods. Here, we used small-molecule microarray screens to identify and characterize drug-like compounds that modulate the biologic function of ETV1. We identified the 1,3,5-triazine small molecule BRD32048 as a top candidate ETV1 perturbagen. BRD32048 binds ETV1 directly, modulating both ETV1-mediated transcriptional activity and invasion of ETV1-driven cancer cells. Moreover, BRD32048 inhibits p300-dependent acetylation of ETV1, thereby promoting its degradation. These results point to a new avenue for pharmacologic ETV1 inhibition and may inform a general means to discover small molecule perturbagens of transcription factor oncoproteins. (C) 2014 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据